These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 17326817)

  • 1. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
    Lourida ES; Georgiadis AN; Papavasiliou EC; Papathanasiou AI; Drosos AA; Tselepis AD
    Arthritis Res Ther; 2007; 9(1):R19. PubMed ID: 17326817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
    Lourida ES; Papathanasiou AI; Goudevenos JA; Tselepis AD
    Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):117-26. PubMed ID: 16843649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
    Papathanasiou AI; Lourida ES; Tsironis LD; Goudevenos JA; Tselepis AD
    Atherosclerosis; 2008 Jan; 196(1):289-297. PubMed ID: 17140582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia.
    Tsouli SG; Kiortsis DN; Lourida ES; Xydis V; Tsironis LD; Argyropoulou MI; Elisaf M; Tselepis AD
    J Lipid Res; 2006 Oct; 47(10):2208-14. PubMed ID: 16888320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against various forms of mildly oxidized low-density lipoprotein are not associated with carotid intima-media thickness in patients with primary hyperlipidemia.
    Tsouli SG; Kiortsis DN; Xydis V; Argyropoulou MI; Elisaf M; Tselepis AD
    Angiology; 2006; 57(5):615-22. PubMed ID: 17067985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution.
    Sánchez-Quesada JL; Vinagre I; de Juan-Franco E; Sánchez-Hernández J; Blanco-Vaca F; Ordóñez-Llanos J; Pérez A
    Am J Cardiol; 2012 Jul; 110(1):67-71. PubMed ID: 22481012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways.
    Wang WY; Li J; Yang D; Xu W; Zha RP; Wang YP
    Cardiovasc Res; 2010 Mar; 85(4):845-52. PubMed ID: 19910444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
    Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
    Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis.
    Peters MJ; van Halm VP; Nurmohamed MT; Damoiseaux J; Tervaert JW; Twisk JW; Dijkmans BA; Voskuyl AE
    J Rheumatol; 2008 Aug; 35(8):1495-9. PubMed ID: 18597411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
    Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
    J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.
    Tellis CC; Tselepis AD
    Biochim Biophys Acta; 2009 May; 1791(5):327-38. PubMed ID: 19272461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes.
    Yang M; Chu EM; Caslake MJ; Edelstein C; Scanu AM; Hill JS
    Biochim Biophys Acta; 2010 Feb; 1801(2):176-82. PubMed ID: 19895904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
    Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
    Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina.
    Gajos G; Zalewski J; Mostowik M; Konduracka E; Nessler J; Undas A
    Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):434-9. PubMed ID: 24555913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments.
    Charniot JC; Khani-Bittar R; Albertini JP; Giral P; Cherfils C; Cosson C; Guillerm E; Leprince P; Gandjbakhch I; Bonnefont-Rousselot D
    Int J Cardiol; 2013 Sep; 168(1):132-8. PubMed ID: 23103135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.
    Shi Y; Zhang P; Zhang L; Osman H; Mohler ER; Macphee C; Zalewski A; Postle A; Wilensky RL
    Atherosclerosis; 2007 Mar; 191(1):54-62. PubMed ID: 16765356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Lp-PLA2 in lipid-lowering therapy.
    Racherla S; Arora R
    Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.